300 related articles for article (PubMed ID: 30185437)
21. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
22. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
[TBL] [Abstract][Full Text] [Related]
23. [The Mechanism of Resveratrol on Acute T-Lymphocyte Leukemia through IL-7-Mediated JAK / STAT Signaling Pathway].
Shi M; Kang PY; Li YY; Wang SH; Zhang YY; Wang WJ; Li YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1715-1723. PubMed ID: 36476894
[TBL] [Abstract][Full Text] [Related]
24. STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of
Van der Zwet JCG; Cordo' V; Buijs-Gladdines JGCAM; Hagelaar R; Smits WK; Vroegindeweij E; Graus LTM; Poort V; Nulle M; Pieters R; Meijerink JPP
Haematologica; 2023 Mar; 108(3):732-746. PubMed ID: 35734930
[TBL] [Abstract][Full Text] [Related]
25. A new hope for early T cell precursor acute lymphoblastic leukemia therapy based on STAT5+ leukemic stem cell targeting.
Pelayo R
J Leukoc Biol; 2023 Oct; 114(5):381-383. PubMed ID: 37607260
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis?
Barata JT; Cardoso AA; Boussiotis VA
Leuk Lymphoma; 2005 Apr; 46(4):483-95. PubMed ID: 16019476
[TBL] [Abstract][Full Text] [Related]
27. Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line.
Rosa Santos SC; Dumon S; Mayeux P; Gisselbrecht S; Gouilleux F
Oncogene; 2000 Feb; 19(9):1164-72. PubMed ID: 10713704
[TBL] [Abstract][Full Text] [Related]
28. IL-7: Comprehensive review.
Winer H; Rodrigues GOL; Hixon JA; Aiello FB; Hsu TC; Wachter BT; Li W; Durum SK
Cytokine; 2022 Dec; 160():156049. PubMed ID: 36201890
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma.
Silva A; Almeida ARM; Cachucho A; Neto JL; Demeyer S; de Matos M; Hogan T; Li Y; Meijerink J; Cools J; Grosso AR; Seddon B; Barata JT
Blood; 2021 Sep; 138(12):1040-1052. PubMed ID: 33970999
[TBL] [Abstract][Full Text] [Related]
30. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
Morishita D; Katayama R; Sekimizu K; Tsuruo T; Fujita N
Cancer Res; 2008 Jul; 68(13):5076-85. PubMed ID: 18593906
[TBL] [Abstract][Full Text] [Related]
31. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival.
Wofford JA; Wieman HL; Jacobs SR; Zhao Y; Rathmell JC
Blood; 2008 Feb; 111(4):2101-11. PubMed ID: 18042802
[TBL] [Abstract][Full Text] [Related]
32. Superoxide-Generating Nox5α Is Functionally Required for the Human T-Cell Leukemia Virus Type 1-Induced Cell Transformation Phenotype.
Shigemura T; Shiohara M; Kato M; Furuta S; Kaneda K; Morishita K; Hasegawa H; Fujii M; Gorlach A; Koike K; Kamata T
J Virol; 2015 Sep; 89(17):9080-9. PubMed ID: 26109726
[TBL] [Abstract][Full Text] [Related]
33. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Vanden Bempt M; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J
Cancer Discov; 2018 May; 8(5):616-631. PubMed ID: 29496663
[TBL] [Abstract][Full Text] [Related]
34. PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene.
Guo Z; Wang A; Zhang W; Levit M; Gao Q; Barberis C; Tabart M; Zhang J; Hoffmann D; Wiederschain D; Rocnik J; Sun F; Murtie J; Lengauer C; Gross S; Zhang B; Cheng H; Patel V; Schio L; Adrian F; Dorsch M; Garcia-Echeverria C; Huang SM
Blood; 2014 Sep; 124(11):1777-89. PubMed ID: 25006129
[TBL] [Abstract][Full Text] [Related]
35. Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
Zhang Q; Lee B; Korecka M; Li G; Weyland C; Eck S; Gessain A; Arima N; Lessin SR; Shaw LM; Luger S; Kamoun M; Wasik MA
Leuk Res; 1999 Apr; 23(4):373-84. PubMed ID: 10229324
[TBL] [Abstract][Full Text] [Related]
36. STAT5 is essential for Akt/p70S6 kinase activity during IL-2-induced lymphocyte proliferation.
Lockyer HM; Tran E; Nelson BH
J Immunol; 2007 Oct; 179(8):5301-8. PubMed ID: 17911616
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-2 family cytokines stimulate phosphorylation of the Pro-Ser-Pro motif of Stat5 transcription factors in human T cells: resistance to suppression of multiple serine kinase pathways.
Nagy ZS; Wang Y; Erwin-Cohen RA; Aradi J; Monia B; Wang LH; Stepkowski SM; Rui H; Kirken RA
J Leukoc Biol; 2002 Oct; 72(4):819-28. PubMed ID: 12377952
[TBL] [Abstract][Full Text] [Related]
38. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.
Gusscott S; Jenkins CE; Lam SH; Giambra V; Pollak M; Weng AP
PLoS One; 2016; 11(8):e0161158. PubMed ID: 27532210
[TBL] [Abstract][Full Text] [Related]
39. Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-mediated development of human thymocyte precursors.
Pallard C; Stegmann AP; van Kleffens T; Smart F; Venkitaraman A; Spits H
Immunity; 1999 May; 10(5):525-35. PubMed ID: 10367898
[TBL] [Abstract][Full Text] [Related]
40. Phosphatidylinositol 3-kinase potentiates, but does not trigger, T cell proliferation mediated by the IL-2 receptor.
Moon JJ; Nelson BH
J Immunol; 2001 Sep; 167(5):2714-23. PubMed ID: 11509615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
